- Data presented at the
Heart Failure Society of America annual scientific meeting - New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failure
Sunday, October 2, 2022
Lexicon: New Data on Sotagliflozin's Effect on Reducing Recurrent Heart Failure
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.